



ASX/media release

24 January 2007

## **52% increase in 1<sup>st</sup> half sales**

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor system which measures central blood pressures non-invasively, announces a 52 per cent increase in unaudited H1 FY2007 sales over H1 FY2006. Sales revenue for the six months ended 31 December 2006 was \$2.6 million, compared to \$1.7 million for the previous corresponding period.

In the United States, sales increased by 90 per cent in H1 FY2007 compared to H1 FY2006, and sales opportunities also increased significantly. In Europe, new distribution agreements and expanded contracts with existing distributors helped sales grow by 67 per cent.

AtCor chief executive officer, Duncan Ross, said that the company's performance was encouraging. "Our sales and distribution teams are in place and the market is becoming increasingly aware of the importance of measuring central blood pressure, highlighting SphygmoCor's ability to assess and manage cardiovascular risk and disease. Our growing sales to the pharmaceutical and research sectors are building a strong foundation for our entry into the clinical practice market."

Results for the period ended 31 December 2006 will be announced on 22 February 2007.

*For further information, please contact:*

Duncan Ross – AtCor Medical CEO  
+1 (630) 799 8221

Peter Manley – AtCor Medical CFO  
+61 2 9874 8761

*Media enquiries to:*

Ashley Rambukwella – Financial & Corporate Relations  
Ph: (61 2) 8264 1004/m. 0407 231 282 or [a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)